Phase I part, Primary objective: the maximum tolerated dose of S-1 in the SLOG regimen
Secondary objectives: the dose-limiting toxicity of the regimen Phase II part, Primary
objective: Overall tumor response rate (by RECIST criteria) Secondary objectives: Disease
control rate (Objective response rate (ORR) + stable disease ≧ 16 weeks), Time to tumor
progression, Progression-free survival, Overall survival ,Safety profile, Biomarker study
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Health Research Institutes, Taiwan
Collaborators:
Chang Gung Memorial Hospital National Cheng-Kung University Hospital National Taiwan University Hospital